Perk Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 8.00 Cr
as on 10-01-2025
- Paid Up Capital ₹ 6.38 Cr
as on 10-01-2025
- Company Age 43 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.85 M
as on 10-01-2025
- Satisfied Charges ₹ 6.36 Cr
as on 10-01-2025
- Revenue 208.04%
(FY 2020)
- Profit 296.18%
(FY 2020)
- Ebitda 60.53%
(FY 2020)
- Net Worth 5.48%
(FY 2020)
- Total Assets 30.42%
(FY 2020)
About Perk Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 8.00 Cr and a paid-up capital of Rs 6.38 Cr.
The company currently has active open charges totaling ₹3.85 M. The company has closed loans amounting to ₹6.36 Cr, as per Ministry of Corporate Affairs (MCA) records.
Monica Kaile, Ritu Kaile, and Krishna Kaile serve as directors at the Company.
- CIN/LLPIN
L24231UP1981PLC005400
- Company No.
005400
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
24 Aug 1981
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Listed
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Meerut, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Perk Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishna Kaile  | Managing Director | 01-Oct-1993 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Monica Kaile | Director | 21-Oct-2015 | Current |
| Ritu Kaile | Whole-Time Director | 21-Oct-2015 | Current |
Financial Performance of Perk Pharmaceuticals.
Perk Pharmaceuticals Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 208.04% increase. The company also saw a substantial improvement in profitability, with a 296.18% increase in profit. The company's net worth moved up by a moderate rise of 5.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Perk Pharmaceuticals?
In 2019, Perk Pharmaceuticals had a promoter holding of 52.30% and a public holding of 47.70%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uno Bank Of India Creation Date: 05 Aug 1987 | ₹0.18 M | Open |
Union Bank Of India Creation Date: 05 Jan 1987 | ₹0.18 M | Open |
Union Bank Of India Creation Date: 05 Jan 1987 | ₹3.50 M | Open |
How Many Employees Work at Perk Pharmaceuticals?
Perk Pharmaceuticals has a workforce of 9 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Perk Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Perk Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
